An interventional study of Silymarin and Placebo in Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis, sponsored by Phramongkutklao College of Medicine and Hospital. Recruiting at 1 site in Thailand. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-02-26.
Sponsored by Phramongkutklao College of Medicine and Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Arthritis, Rheumatoid with a site in Thailand — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Thailand.
Among the 37 studies in Arthritis, Rheumatoid with a site in Thailand, this one is the 33rd largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2024, is one of 2 with no phase, and was the 36th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 37 studies in Arthritis, Rheumatoid with a site in Thailand are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Thailand, Australia, Belgium and 8 more countries
Ages 18–75
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 25 · Phase 4 3
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 651 across the 36 interventional studies, 5,383 across the 1 observational. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 37 have an industry lead sponsor. The 10 most frequent:
Phramongkutklao College of Medicine and Hospital is the lead sponsor of 37 studies on the registry; 7 are open to participants now.
Phramongkutklao College of Medicine and Hospital has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Arthritis, Rheumatoid with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To study the effect of silymarin against methotrexate-induced liver injury in rheumatic diseases including rheumatoid arthritis, psoriatric arthritis and psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis at least one of the following
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Silymarin 140 mg oral tid pc + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks
Drug: Silymarin
Placebo + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks
Drug: Placebo
Silymarin is randomly assigned to the participants for 12 weeks during study.
Also known as: Milk Thistle
Placebo is randomly assigned to the participants for 12 weeks during study.
AST or ALT > 1X ULN ( normal AST and ALT 0-50 U/L)
elevation of AST or ALT more than 1X ULN (% participant)
Time frame: 12 weeks
AST or ALT > 2X ULN ( normal AST and ALT 0-50 U/L) AST or ALT > 2X ULN AST or ALT > 2X ULN
elevation of AST or ALT more than 2X ULN (% participant)
Time frame: 12 weeks
AST or ALT > 3X ULN ( normal AST and ALT 0-50 U/L)
elevation of AST or ALT more than 3X ULN (% participant)
Time frame: 12 weeks
AST or ALT > 5X ULN or >3X ULN ( normal AST and ALT 0-50 U/L) with symptom of hepatitis such as Fatique, abdominal pain, nausea, vomiting or total bilirubin > 2X with jaundice
elevation of AST or ALT \> 5X ULN or \>3X ULN with symptom of hepatitis such as Fatique, abdominal pain, nausea, vomiting or total bilirubin \> 2X with jaundice (% participant)
Time frame: 12 weeks
Discontinuation rate of methotrexate
Rate of methotrexate discontinuation (%)
Time frame: 12 weeks
Adverse events
Rate of any adverse events (%)
Time frame: 12 weeks
Change of DAS-28 ESR or CRP Score
Change of DAS-28 ESR or CRP Score for patients with Rheumatoid arthritis and psoriatric arthritis (unit)
Time frame: 12 weeks
Change of BASDAI Score
Change of BASDAI Score for AS (unit)
Time frame: 12 weeks
Change of ASDAS ESR or CRP Score
Change of ASDAS ESR or CRP Score for AS (unit)
Time frame: 12 weeks
Change of BSA for psoriasis
Change of BSA for psoriasis (unit)
Time frame: 12 weeks
Plan to share: Yes — Study Protocol is to be shared with others. Full data would become available by mid 2026.
Supporting information: Study protocol
Time frame: mid 2026
Access criteria: IPD Sharing Access Criteria has not been decided.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Apr 2025, 14 months after the start.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 14 months is below that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silymarin
Phramongkutklao College of Medicine and Hospital